At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- LY4584180 (drug), Rituximab (drug)
- How long the study runs
- Study runs about 46 months (dates as stated)
- About the drug or intervention
- LY4584180 — drug: administered orally · Rituximab — drug: administered through IV infusion
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 460
- Started
- 2026-04-17
- Last checked
- 2026-10
Plain English Summary
What is this study?
- • Testing a new treatment for lymphoma, non-hodgkin's
- • Phase1 - 460 participants
- • The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with lymphoma, non-hodgkin's
Where?
- • London - King's College Hospital
- • London - The Royal Marsden NHS Foundation Trust
- • Nottingham - Nottingham City Hospital
- • Plymouth - Derriford Hospital
- • +1 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Biomarkers mentioned
What the study is looking for
- ✓Has been treated for the following blood cancers and has received at least 2 previous treatments or not...
- ✓Diffuse large B-cell lymphoma - not otherwise specified
- ✓High-grade B-cell lymphoma
- ✓Diffuse large B-cell lymphoma - transformed from indolent lymphomas
- ✓Follicular large B-cell lymphoma
Who cannot take part
- ✗Has an active second cancer
- ✗Has known Cytomegalovirus infection. Participants with negative status are eligible
- ✗Has known hepatitis B or C infection or uncontrolled HIV
- ✗Has known significant heart disease
See the full criteria
Where Is This Study? (5 UK sites)
King's College Hospital
London SE5 9RS, United Kingdom
The Royal Marsden NHS Foundation Trust
London SW3 6JJ, United Kingdom
Nottingham City Hospital
Nottingham NG5 1PB, United Kingdom
Derriford Hospital
Plymouth PL6 8DH, United Kingdom
University Hospital Southampton NHS Foundation Trust
Southampton SO16 6YD, United Kingdom
How to Get in Touch
Trial question or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Sponsor contactCONTACT
Physicians interested in becoming principal investigators please contact
Sponsor contactCONTACT